Lumigan Related Published Studies
Well-designed clinical trials related to Lumigan (Bimatoprost)
Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized,
double-masked, vehicle-controlled, parallel-group study. [2012]
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10]
Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. [2011.09.05]
The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed
combination versus bimatoprost in patients who switched from timolol. [2011]
Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study. [2010.12]
Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. [2010.10]
Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium-aluminum-garnet laser posterior capsulotomy. [2010.10]
The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma. [2010.10]
Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. [2010.05]
Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. [2010.05]
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. [2010.04]
Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN. [2010.04]
Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. [2010.02]
Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. [2010.01]
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and
0.03% in patients with glaucoma or ocular hypertension. [2010]
A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. [2009.10]
Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. [2009.10]
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. [2009.06]
Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. [2009.04]
Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. [2008.10]
Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. [2008.09]
Long-Term Efficacy and Safety of Bimatoprost for Intraocular Pressure Lowering in Glaucoma and Ocular Hypertension: Year 4. [2008.07.11]
Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. [2008.06.11]
Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. [2008.05]
Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. [2008.04]
Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%. [2008.04]
Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. [2007.12]
Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. [2007.06]
A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. [2007.05]
Effect of bimatoprost on intraocular pressure after phacoemulsification in eyes with exfoliation syndrome. [2007.05]
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on Circadian Intraocular Pressure. [2007.04.23]
24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. [2007.04]
A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. [2007.02]
A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. [2007.01]
Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. [2006.12]
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. [2006.05]
The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery. [2006.02]
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. [2006.02]
Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%. [2006.01]
The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats. [2005.07]
Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma. [2005.06]
Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. [2005.05]
Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. [2005.05]
Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. [2005.02]
Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. [2004.12]
Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. [2004.09]
A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. [2004.09]
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. [2004.08]
Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. [2004.07]
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. [2004.03]
24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. [2004.03]
A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. [2004.03]
Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. [2004.03]
Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. [2003.12]
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. [2003.12]
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. [2003.05]
Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. [2003.03]
Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. [2003.03]
Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. [2003.03]
Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. [2003.01]
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. [2003.01]
A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. [2003.01]
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. [2002.10]
Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. [2001.06]
Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. [2001.05]
Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. [2001.05]
Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. [2001.05]
Well-designed clinical trials possibly related to Lumigan (Bimatoprost)
[Comparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucoma]. [2011.02]
Enhanced eyelashes: prescription and over-the-counter options. [2011.02]
Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. [2010.10]
Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). [2010.09]
Enhanced Eyelashes: Prescription and Over-the-Counter Options. [2010.08.21]
Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. [2010.06]
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. [2008.11.19]
A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. [2008.04]
Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. [2008.02]
The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. [2008.02]
The effect of ocular hypotensive agents on macula. [2007.12]
Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. [2005.02]
Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. [2004.09]
Effect of ibopamine on aqueous humor production in normotensive humans. [2003.11]
Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. [2001.07]
Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. [2001.01]
Other research related to Lumigan (Bimatoprost)
Comparison of Human Ocular Distribution of Bimatoprost and Latanoprost. [2011.12.02]
Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. [2011.11]
Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride. [2011.02]
Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension. [2011.02]
Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. [2011.01]
Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360 degrees synechial angle-closure glaucoma: a preliminary study. [2011.01]
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. [2011]
A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. [2010.12.06]
A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. [2010.12]
Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy. [2010.12]
Bimatoprost 0.03% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Spike Following Neodymium:Yttrium–Aluminum–Garnet Laser Posterior Capsulotomy. [2010.09.28]
Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. [2010.09]
Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. [2010.09]
Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. [2010.06]
Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth. [2010.04.01]
Evaluation of the effect of bimatoprost/timolol fixed combination on ocular blood flow in patients with ocular hypertension using colour Doppler imaging. Preliminary study. [2010.04]
|
